loading...| Preferred Name |
Azeliragon |
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C174675 |
| CAS_Registry |
603148-36-3 |
| code |
C174675 |
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923 |
| Contributing_Source |
CTRP FDA |
| DEFINITION |
An orally bioavailable inhibitor of the receptor for advanced glycation end-products (RAGE), with potential antineoplastic activity. Upon oral administration, azeliragon targets and binds to RAGE, thereby preventing binding of RAGE ligands to RAGE, and prevents RAGE-mediated signaling, This may inhibit proliferation and induce apoptosis of tumor cells in which the RAGE pathway is overactivated. RAGE, a receptor belonging to the immunoglobulin superfamily, plays a key role in inflammation and is overexpressed in a variety of cancers. It plays a key role in tumor cell proliferation, survival and metastasis. |
| Display_Name |
Azeliragon |
| FDA_UNII_Code |
LPU25F15UQ |
| FULL_SYN |
AZELIRAGON Azeliragon PF-04494700 TTP488 |
| label |
Azeliragon |
| NCI_Drug_Dictionary_ID |
811889 |
| NCI_META_CUI |
CL1412175 |
| Preferred_Name |
Azeliragon |
| prefixIRI |
Thesaurus:C174675 |
| prefLabel |
Azeliragon |
| Semantic_Type |
Pharmacologic Substance |
| subClassOf |
| Delete | Mapping To | Ontology | Source |
|---|---|---|---|
| http://purl.bioontology.org/ontology/MESH/C000655744 | Medical Subject Headings / 医学主题词表 | LOOM |